NCCN Recommendation

NCCN Recommendation
National Comprehensive Cancer Network® (NCCN®)
Axitinib (INLYTA®) + pembrolizumab is a first-line treatment option recommended across all 3 IMDC risk groups in advanced clear-cell RCC by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer1
Favorable risk: preferred (category 2A*)
Intermediate/poor risk: preferred (category 1)
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
*Category 2A: Based on lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 1: Based on high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
IMDC=International Metastatic RCC Database Consortium.
Reference
1. 
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kidney Cancer V.2.2020. © National Comprehensive Cancer Network, Inc 2019. All rights reserved. Accessed July 1, 2020. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.
BAVENCIO is a registered trademark of Merck KGaA, Darmstadt, Germany. All other trademarks are property of their respective owners.